FDA approves first generic version of rifapentine for tuberculosis treatment.

The U.S. Food and Drug Administration has authorized the first generic version of Priftin (rifapentine) tablets. This approval provides an additional option for managing active tuberculosis and preventing latent infections, which affect millions in the United States.